Advertisement
Loading...

Alvotech

ALVONASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$3.31
$-0.12(-3.50%)
U.S. Market opens in 28h 22m

Alvotech Fundamental Analysis

Alvotech (ALVO) shows weak financial fundamentals with a PE ratio of 33.00, profit margin of 4.76%, and ROE of -11.92%. The company generates $0.7B in annual revenue with strong year-over-year growth of 19.74%.

Key Strengths

Cash Position18.65%
PEG Ratio-0.93
Current Ratio1.89

Areas of Concern

ROE-11.92%
We analyze ALVO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 91.1/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
91.1/100

We analyze ALVO's fundamental strength across five key dimensions:

Efficiency Score

Weak

ALVO struggles to generate sufficient returns from assets.

ROA > 10%
1.88%

Valuation Score

Moderate

ALVO shows balanced valuation metrics.

PE < 25
33.00
PEG Ratio < 2
-0.93

Growth Score

Moderate

ALVO shows steady but slowing expansion.

Revenue Growth > 5%
19.74%
EPS Growth > 10%
1.11%

Financial Health Score

Excellent

ALVO maintains a strong and stable balance sheet.

Debt/Equity < 1
-5.09
Current Ratio > 1
1.89

Profitability Score

Weak

ALVO struggles to sustain strong margins.

ROE > 15%
-1192.02%
Net Margin ≥ 15%
4.76%
Positive Free Cash Flow
No

Key Financial Metrics

Is ALVO Expensive or Cheap?

P/E Ratio

ALVO trades at 33.00 times earnings. This suggests a premium valuation.

33.00

PEG Ratio

When adjusting for growth, ALVO's PEG of -0.93 indicates potential undervaluation.

-0.93

Price to Book

The market values Alvotech at -3.24 times its book value. This may indicate undervaluation.

-3.24

EV/EBITDA

Enterprise value stands at -3.16 times EBITDA. This is generally considered low.

-3.16

How Well Does ALVO Make Money?

Net Profit Margin

For every $100 in sales, Alvotech keeps $4.76 as profit after all expenses.

4.76%

Operating Margin

Core operations generate 13.34 in profit for every $100 in revenue, before interest and taxes.

13.34%

ROE

Management delivers $-11.92 in profit for every $100 of shareholder equity.

-11.92%

ROA

Alvotech generates $1.88 in profit for every $100 in assets, demonstrating efficient asset deployment.

1.88%

Following the Money - Real Cash Generation

Operating Cash Flow

Alvotech generates limited operating cash flow of $-56.10M, signaling weaker underlying cash strength.

$-56.10M

Free Cash Flow

Alvotech generates weak or negative free cash flow of $-128.16M, restricting financial flexibility.

$-128.16M

FCF Per Share

Each share generates $-0.41 in free cash annually.

$-0.41

FCF Yield

ALVO converts -10.99% of its market value into free cash.

-10.99%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

33.00

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.93

vs 25 benchmark

P/B Ratio

Price to book value ratio

-3.24

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.76

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-5.09

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.89

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.12

vs 25 benchmark

ROA

Return on assets percentage

0.02

vs 25 benchmark

ROCE

Return on capital employed

0.07

vs 25 benchmark

How ALVO Stacks Against Its Sector Peers

MetricALVO ValueSector AveragePerformance
P/E Ratio33.0028.62 Worse (Expensive)
ROE-11.92%783.00% Weak
Net Margin4.76%-48181.00% (disorted) Weak
Debt/Equity-5.090.39 Strong (Low Leverage)
Current Ratio1.894.12 Neutral
ROA1.88%-21914.00% (disorted) Weak

ALVO outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Alvotech's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-1.48%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

101.84%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

92.44%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ